The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 5,000
- 试验地点
- 3
- 主要终点
- Overall survival
研究概览
简要总结
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).
The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of unresectable hepatocellular carcinoma
- •Able to comprehend and provide written informed consent in accordance with institutional guidelines.
排除标准
- •Patients not willing to participate and/or give their written informed consent.
结局指标
主要结局
Overall survival
时间窗: Up to 5 years
Overall survival (OS) is defined as the time (days) from the date of unresectable HCC diagnosis to the date of death, due to any reason. Patients alive or lost to follow-up at the time of analysis will be censored at their last date of follow-up
次要结局
- Progression-free survival (PFS)(Up to 5 years)
- Time to progression (TTP)(Up to 5 years)
- Frequency and Severity of Adverse Events(Up to 5 years)
- Duration of treatment(Up to 5 years)